SINGULAIR works differently –
blocks leukotrienes, an underlying cause of allergy symptoms.
For adults
- Seasonal allergic rhinitis
- Perennial allergic rhinitis
For pediatric and
adolescent patients
Indicated for relief of symptoms in patients as young as:
- 6 months with perennial
allergic rhinitis - 2 years with seasonal
allergic rhinitis
SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).
Important Information
In clinical trials, SINGULAIR was generally well tolerated, with a safety profile similar to that of placebo. Adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of >1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.
Before prescribing SINGULAIR, please read the Prescribing Information.
20753522(18)-03/09-SNG
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck & Co., Inc.